Adaptimmune Therapeutics plc
ADAP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $63,302 | $50,634 | $137,876 | $243,083 |
| - Cash | $26,061 | $41,054 | $91,139 | $116,741 |
| + Debt | $48,680 | $48,706 | $74,209 | $74,495 |
| Enterprise Value | $85,921 | $58,286 | $120,946 | $200,837 |
| Revenue | $13,677 | $7,285 | $3,222 | $40,901 |
| % Growth | 87.7% | 126.1% | -92.1% | – |
| Gross Profit | $11,176 | $6,406 | $3,222 | $40,901 |
| % Margin | 81.7% | 87.9% | 100% | 100% |
| EBITDA | -$26,257 | -$42,662 | -$67,974 | -$12,859 |
| % Margin | -192% | -585.6% | -2,109.7% | -31.4% |
| Net Income | -$30,340 | -$47,584 | -$74,215 | -$17,617 |
| % Margin | -221.8% | -653.2% | -2,303.4% | -43.1% |
| EPS Diluted | -0.12 | -0.19 | -0.29 | -0.069 |
| % Growth | 36.8% | 34.5% | -320.3% | – |
| Operating Cash Flow | -$34,780 | -$66,592 | -$34,204 | -$54,451 |
| Capital Expenditures | -$75 | -$1,203 | -$1,173 | -$435 |
| Free Cash Flow | -$34,855 | -$66,592 | -$35,377 | -$54,886 |